Rigel (RIGL)
NASDAQ:RIGL
Earnings Data
Report Date
May 05, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.84Last Year’s EPS
0.63Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial progress: materially higher net product sales (232M, +60% YoY), strong Q4 growth (+41% YoY), profitable operations and a doubled cash position, alongside encouraging early clinical data for R289 with regulatory designations. However, several important caveats were emphasized: a large portion of reported GAAP net income resulted from a noncash deferred tax benefit, parts of 2025 growth were aided by one-time affordability and gross-to-net effects, and R289 efficacy data remain from a small, heavily pretreated cohort requiring confirmatory data. Management set conservative yet growth-positive 2026 guidance and outlined disciplined BD and clinical milestones. Balancing robust commercial momentum and promising early clinical signals versus accounting-driven income effects, one-time drivers, and clinical/BD execution risks, the overall tone is optimistic with measured caution.Company Guidance
Product-Level Sales Momentum
Q4 2025 sales by product: TAVALISSE $45.6M (+47% YoY), GAVRETO $10.2M (+27% YoY), REZLIDHIA $9.6M (+29% YoY).
Profitability and Cash Position
Rigel reported GAAP net income of $367.0 million for full-year 2025 (vs. $17.5M in 2024) and ended 2025 with $155.0 million in cash, cash equivalents and short-term investments (up from $77.3M at end-2024, ~+100%).
Encouraging Clinical Data for R289 (Phase Ib)
In heavily pretreated lower-risk MDS patients (dose escalation, n=33), among 18 evaluable patients at ≥500 mg daily doses, 6 (33%) achieved red cell transfusion independence (RBC-TI ≥8 weeks); median RBC-TI duration ~23 weeks and median time to onset ~2 months. Safety profile: generally well tolerated with low incidence of Grade 3/4 cytopenias/infections and one DLT (Grade 3/4 AST/ALT at 750 mg).
Regulatory Incentives for R289
R289 holds FDA Fast Track designation and orphan drug designation for MDS, supporting an expedited regulatory pathway and potential market exclusivity upon approval.
Proven BD & Portfolio Expansion Track Record
Successful in-licensing/acquisitions of REZLIDHIA (2022) and GAVRETO (2024) illustrate the company’s strategy of leveraging existing commercial infrastructure to scale revenues with limited integration costs.
Positive 2026 Financial Guidance
Guidance for 2026: total revenue $275M–$290M, net product sales $255M–$265M, contract revenues $20M–$25M, and expectation of positive net income while funding clinical programs.
Strong Full-Year Net Product Sales Growth
Net product sales for 2025 were $232.0 million, an increase of $87 million or 60% versus 2024, driven by demand across the three-product portfolio and portfolio expansion.
Record Fourth Quarter Performance
Fourth quarter 2025 net product sales were $65.4 million, up $18.9 million or 41% year-over-year, marking a record quarter.
RIGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RIGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | $33.02 | $29.63 | -10.27% |
Nov 04, 2025 | $28.38 | $37.85 | +33.37% |
Aug 05, 2025 | $24.24 | $29.81 | +22.98% |
May 06, 2025 | $18.26 | $18.47 | +1.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rigel (RIGL) report earnings?
Rigel (RIGL) is schdueled to report earning on May 05, 2026, After Close (Confirmed).
What is Rigel (RIGL) earnings time?
Rigel (RIGL) earnings time is at May 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RIGL EPS forecast?
RIGL EPS forecast for the fiscal quarter 2026 (Q1) is 0.84.